Notably, our dataset also confirms biomarkers (such as CCL17, PDGF, SPARC) previously identified in early IPF, as well as demonstrates correlation of CXCL12 to lung function, suggesting that many biomarkers identified in our late stage IPF cohort may also be potential early diagnostic markers. This evidence concerns the gene CXCL12 and idiopathic pulmonary fibrosis.